Market Overview :
The latest research study “Legal Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global legal cannabis market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027
Cannabis is a tall plant with an upright stem used as a drug for its psychoactive properties. It is obtained from a group of three plants, namely cannabis Sativa, Indica, and Ruderalis. Cannabis is known to treat various symptoms and diseases like cancer, arthritis, migraines, glaucoma, epilepsy, multiple sclerosis, Parkinson’s, Alzheimer’s, Tourette’s, amyotrophic lateral sclerosis (ALS), AIDS, and post-traumatic stress disorder (PTSD). Healthcare professionals and doctors recommend cannabis-based products to relieve chronic pain, reduce anxiety, regulate and prevent diabetes, and treat depression and inflammatory bowel syndrome.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/legal-cannabis-market/requestsample
Legal Cannabis Market Trends and Drivers:
The global legal cannabis market is primarily driven by the growing medical applications of the plant. The rising geriatric population that needs medicine for chronic pain is also fueling the market growth. In addition to this, the positive effect of cannabis legalization on public health and safety is propelling the market growth.
Governments and international agencies across countries such as the United States and Canada are regulating cannabis cultivation and sales by application, ensuring its contribution to the GDP of the nations. Nowadays, doctors are prescribing cannabis oil to children, which is showing tremendous benefits for treating disorders such as epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome.
Furthermore, the increasing number of legal cannabis dispensaries, along with the growing research and clinical trials, is expected to positively impact the market in the upcoming years.
|Legal Cannabis Market Report Scope|
|Market size value in 2021||US$ XX Billion|
|Market forecast in 2027||US$ XX Billion|
|Growth Rate||CAGR of XX% from 2022 to 2027|
|Base year for estimation||2021|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Segments covered||source, derivatives, distribution channel and end user|
|Regional scope||North America, Europe, Asia-Pacific, Europe, Latin America, Middle East and Africa|
|Key companies profiled||Aurora Cannabis Inc., Cannabis Sativa Inc., Canopy Growth Corporation, Green Thumb Industries, GW Pharmaceuticals plc (Jazz Pharmaceuticals plc), HEXO Corp., Organigram Holdings Inc., Sundial Growers Inc., The Cronos Group, The Green Organic Dutchman Holdings Ltd., The Scotts Miracle-Gro Company, Tilray and VIVO Cannabis Inc.|
|Market Dynamics||Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,|
|Customization preview||If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.|
Global Legal Cannabis Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Aurora Cannabis Inc., Cannabis Sativa Inc., Canopy Growth Corporation, Green Thumb Industries, GW Pharmaceuticals plc (Jazz Pharmaceuticals plc), HEXO Corp., Organigram Holdings Inc., Sundial Growers Inc., The Cronos Group, The Green Organic Dutchman Holdings Ltd., The Scotts Miracle-Gro Company, Tilray and VIVO Cannabis Inc.
The report has segmented the market on the basis of region, source, derivatives, distribution channel and end user.
Breakup by Source:
Breakup by Derivatives:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
Breakup by Distribution Channel:
- Recreational Stores
- Online Stores
Breakup by End User:
- Medical Use
- Recreational Use
- Industrial Use
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800